Honz Pharmaceutical Co., Ltd. (300086.SZ)
CNY 4.36
(3.32%)
CNY 4.36
(3.32%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 133.53 Million CNY | 239.02% |
| 2022 | -143.87 Million CNY | -181.05% |
| 2021 | 98.11 Million CNY | -0.73% |
| 2020 | 107.17 Million CNY | 39.51% |
| 2019 | 56 Million CNY | -27.53% |
| 2018 | 99.78 Million CNY | 7.26% |
| 2017 | 123.94 Million CNY | -3.19% |
| 2016 | 98.34 Million CNY | -23.46% |
| 2015 | 141.3 Million CNY | 47.85% |
| 2014 | 100.48 Million CNY | 79.85% |
| 2013 | 55.86 Million CNY | -19.79% |
| 2012 | 69.61 Million CNY | 195.32% |
| 2011 | 23.58 Million CNY | -86.49% |
| 2010 | 174.7 Million CNY | 46.74% |
| 2009 | 119.24 Million CNY | 86.44% |
| 2008 | 63.82 Million CNY | 61.48% |
| 2007 | 39.52 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -48.86 Million CNY | -85.11% |
| 2024 Q1 | -44 Million CNY | -137.41% |
| 2024 Q3 | -19.14 Million CNY | 60.83% |
| 2023 Q2 | 4.68 Million CNY | -77.52% |
| 2023 Q1 | 20.83 Million CNY | 141.77% |
| 2023 Q4 | 62.19 Million CNY | 296.74% |
| 2023 Q3 | -31.61 Million CNY | -774.84% |
| 2023 FY | - CNY | 239.02% |
| 2022 Q1 | -41.56 Million CNY | -146.57% |
| 2022 FY | - CNY | -181.05% |
| 2022 Q4 | -49.89 Million CNY | -148.22% |
| 2022 Q3 | -20.1 Million CNY | 42.14% |
| 2022 Q2 | -34.73 Million CNY | 16.42% |
| 2021 Q4 | 89.25 Million CNY | 274.46% |
| 2021 Q3 | 23.83 Million CNY | 252.75% |
| 2021 Q1 | -23.64 Million CNY | -160.15% |
| 2021 Q2 | -15.6 Million CNY | 34.0% |
| 2021 FY | - CNY | -0.73% |
| 2020 FY | - CNY | 39.51% |
| 2020 Q2 | 34.43 Million CNY | 946.53% |
| 2020 Q3 | 3.26 Million CNY | -90.51% |
| 2020 Q4 | 39.31 Million CNY | 1103.3% |
| 2020 Q1 | -4.06 Million CNY | 39.51% |
| 2019 Q2 | -17.26 Million CNY | -140.91% |
| 2019 FY | - CNY | -27.53% |
| 2019 Q1 | 42.19 Million CNY | 719.15% |
| 2019 Q4 | -6.72 Million CNY | -232.12% |
| 2019 Q3 | 5.09 Million CNY | 129.49% |
| 2018 Q1 | 13.48 Million CNY | -65.45% |
| 2018 Q3 | 22.84 Million CNY | -29.99% |
| 2018 FY | - CNY | 7.26% |
| 2018 Q4 | -6.81 Million CNY | -129.84% |
| 2018 Q2 | 32.62 Million CNY | 141.93% |
| 2017 Q4 | 39.03 Million CNY | 385.25% |
| 2017 FY | - CNY | -3.19% |
| 2017 Q1 | 6.49 Million CNY | -84.65% |
| 2017 Q2 | 34.33 Million CNY | 428.76% |
| 2017 Q3 | 8.04 Million CNY | -76.58% |
| 2016 Q3 | 8.37 Million CNY | -48.45% |
| 2016 Q4 | 42.3 Million CNY | 405.31% |
| 2016 Q1 | 17.67 Million CNY | -79.19% |
| 2016 FY | - CNY | -23.46% |
| 2016 Q2 | 16.24 Million CNY | -8.13% |
| 2015 Q2 | 24.29 Million CNY | 246.26% |
| 2015 Q4 | 84.93 Million CNY | 855.15% |
| 2015 Q3 | 8.89 Million CNY | -63.4% |
| 2015 FY | - CNY | 47.85% |
| 2015 Q1 | -16.61 Million CNY | -193.62% |
| 2014 Q4 | 17.74 Million CNY | 35.29% |
| 2014 Q3 | 13.11 Million CNY | -27.92% |
| 2014 Q2 | 18.19 Million CNY | 213.86% |
| 2014 Q1 | 5.79 Million CNY | -31.32% |
| 2014 FY | - CNY | 79.85% |
| 2013 Q2 | 25.72 Million CNY | 1211.45% |
| 2013 FY | - CNY | -19.79% |
| 2013 Q4 | 8.44 Million CNY | 547.39% |
| 2013 Q3 | 1.3 Million CNY | -94.93% |
| 2013 Q1 | -2.31 Million CNY | -105.72% |
| 2012 Q4 | 40.45 Million CNY | 4957.49% |
| 2012 Q2 | -7.05 Million CNY | -39.2% |
| 2012 Q3 | 799.84 Thousand CNY | 111.33% |
| 2012 Q1 | -5.07 Million CNY | -125.75% |
| 2012 FY | - CNY | 195.32% |
| 2011 Q3 | -19.24 Million CNY | -54.82% |
| 2011 Q4 | 19.69 Million CNY | 202.31% |
| 2011 FY | - CNY | -86.49% |
| 2011 Q1 | 11.48 Million CNY | -80.45% |
| 2011 Q2 | -12.43 Million CNY | -208.26% |
| 2010 Q3 | 45.76 Million CNY | 38.98% |
| 2010 Q2 | 32.93 Million CNY | 12.43% |
| 2010 FY | - CNY | 46.74% |
| 2010 Q1 | 29.29 Million CNY | -3.16% |
| 2010 Q4 | 58.73 Million CNY | 28.34% |
| 2009 Q2 | 21.72 Million CNY | 41.42% |
| 2009 FY | - CNY | 86.44% |
| 2009 Q1 | 15.36 Million CNY | 0.0% |
| 2009 Q4 | 30.24 Million CNY | -32.32% |
| 2009 Q3 | 44.69 Million CNY | 105.67% |
| 2008 FY | - CNY | 61.48% |
| 2007 FY | - CNY | 0.0% |